Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC	cancer, neoplasm	Not yet recruiting	Phase 2	2026-04-30		NCT07041788

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Qilu Pharmaceutical Co., Ltd.	126
Second Affiliated Hospital of Nanchang University	90

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The Second Affiliated Hospital of Nanchang University	Nanchang	China	45

Clinical trials